MedWatch

Eli Lilly acquires biotech firm in new insulin venture

A new form of insulin drugs at Protomer Technoloigies caught the eye of Eli Lilly, which has bought the firm for a sum that could surpass USD 1bn (DKK 6.3bn).

Photo: Mike Blake/REUTERS / X00030

US pharmaceutical company Eli Lilly has entered into an agreement to acquire biotech company Protomer Technologies for a price that could total more than USD 1bn. The final figure will be dependent on future performance and milestone payments.

Protomer Technologies owns a peptide and protein platform which can identify and measure substances including glucose.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs